Therapy brings long-term hope for halting Parkinson’s Disease
By Hudson Institute communications
How deep brain stimulation therapy could help to slow or halt the progression of Parkinson’s Disease is the focus of new research by Dr Joohyung Lee, thanks to a grant from the Bethlehem Griffiths Research Foundation.
“Parkinson’s disease (PD) is primarily associated with the inability to initiate and control voluntary movement. These symptoms result from the loss of brain cells that produce a chemical called dopamine, which acts as a signal to initiate movement,” Dr Lee said.
Current therapies for Parkinson’s Disease improve quality of life for patients by relieving symptoms but do not target the root cause – the loss of dopamine producing cells.
Deep brain stimulation therapy is a procedure that uses a surgically implanted, battery-operated medical device called a neurostimulator (like a heart pacemaker) to deliver electrical stimulation to targeted areas in the brain that control movement to relieve symptoms.
Dr Lee explained that deep brain stimulation (DBS) therapy blocks the abnormal nerve signals that cause PD symptoms.
“We will aim to show how this therapy, used to improve day-to-day quality life for patients, could also hold longer term benefits for people with this debilitating neurological disorder,” he said.
An estimated four people per 1000 in Australia have Parkinson’s disease, increasing to one in 100 over the age of 60. In Australia, there are approximately 80,000 people living with Parkinson’s disease.
“This is a relatively safe procedure that has been shown to improve daily tasks for patients. Over the past few decades, it has been shown to provide remarkable therapeutic effects in carefully selected patients,” Dr Lee said.
Some studies have hinted DBS may slow the overall progression of Parkinson’s Disease but the findings were inconclusive.
“This research will show whether DBS can slow or halt the disease progression in a clinically relevant model of Parkinson’s Disease. Our ultimate aim is to develop a treatment that slows this relentlessly progressive and debilitating illness to improve the lives of people around the world,” Dr Lee said.
Team | Dr Joohyung Lee, Professor Dominic Thyagarajan
Supporter | Bethlehem Griffiths Research Foundation
Contact us
Hudson Institute communications
t: + 61 3 8572 2697
e: communications@hudson.org.au
About Hudson Institute
Hudson Institute’ s research programs deliver in three areas of medical need – inflammation, cancer, women’s and newborn health. More
Hudson News
Get the inside view on discoveries and patient stories
“Thank you Hudson Institute researchers. Your work brings such hope to all women with ovarian cancer knowing that potentially women in the future won't have to go through what we have!”